PCVX Vaxcyte, Inc.

NASDAQ
$58.07

Vaxcyte, Inc. (PCVX) is expected to report earnings on November 4, 2026, after the market close. The consensus earnings estimate is a loss of $1.84 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +5.3% since its last earnings release on August 5, 2026.

Vaxcyte, Inc. Missed Consensus Estimates
Wednesday, August 5, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 4
Wednesday · 4:05 PM ET
Earnings Whisper
-
vs ($1.84)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $58.75

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Vaxcyte, Inc.

Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.

Sector

Healthcare

Industry

Biotechnology